KR20050091713A - 항-시디3 항체를 이용한 궤양성 대장염의 치료 방법 - Google Patents

항-시디3 항체를 이용한 궤양성 대장염의 치료 방법 Download PDF

Info

Publication number
KR20050091713A
KR20050091713A KR1020057010239A KR20057010239A KR20050091713A KR 20050091713 A KR20050091713 A KR 20050091713A KR 1020057010239 A KR1020057010239 A KR 1020057010239A KR 20057010239 A KR20057010239 A KR 20057010239A KR 20050091713 A KR20050091713 A KR 20050091713A
Authority
KR
South Korea
Prior art keywords
antibody
patients
patient
visilizumab
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057010239A
Other languages
English (en)
Korean (ko)
Inventor
이안 월터스
Original Assignee
프로테인 디자인 랩스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테인 디자인 랩스 인코포레이티드 filed Critical 프로테인 디자인 랩스 인코포레이티드
Publication of KR20050091713A publication Critical patent/KR20050091713A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020057010239A 2002-12-05 2003-12-05 항-시디3 항체를 이용한 궤양성 대장염의 치료 방법 Withdrawn KR20050091713A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43164902P 2002-12-05 2002-12-05
US60/431,649 2002-12-05
US45018303P 2003-02-25 2003-02-25
US60/450,183 2003-02-25

Publications (1)

Publication Number Publication Date
KR20050091713A true KR20050091713A (ko) 2005-09-15

Family

ID=32511592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057010239A Withdrawn KR20050091713A (ko) 2002-12-05 2003-12-05 항-시디3 항체를 이용한 궤양성 대장염의 치료 방법

Country Status (7)

Country Link
US (1) US20040253237A1 (https=)
EP (1) EP1567192A4 (https=)
JP (1) JP2006511620A (https=)
KR (1) KR20050091713A (https=)
AU (1) AU2003298015A1 (https=)
CA (1) CA2508264A1 (https=)
WO (1) WO2004052397A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1687066T3 (da) 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
WO2007026742A1 (ja) * 2005-08-30 2007-03-08 Ajinomoto Co., Inc. 大腸デリバリー型炎症性大腸疾患治療薬
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
AU2012201443B2 (en) * 2006-06-06 2014-04-03 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN118562007A (zh) * 2019-12-19 2024-08-30 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19905012A1 (de) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Arzneimittel enthaltend Anti-CD3- und Anti-Fcgamma-R-Antikörper zur begleitenden Behandlung bei Organtransplantationen
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors

Also Published As

Publication number Publication date
US20040253237A1 (en) 2004-12-16
WO2004052397A1 (en) 2004-06-24
AU2003298015A1 (en) 2004-06-30
CA2508264A1 (en) 2004-06-24
JP2006511620A (ja) 2006-04-06
EP1567192A4 (en) 2006-02-08
EP1567192A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
KR20050091713A (ko) 항-시디3 항체를 이용한 궤양성 대장염의 치료 방법
Baldo Chimeric fusion proteins used for therapy: indications, mechanisms, and safety
KR102167261B1 (ko) 관절염 치료
KR102887037B1 (ko) 호중구 질환을 치료하는 방법
KR102326482B1 (ko) 피부과학적 병리의 치료
US20250051446A1 (en) Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
CN103476800B (zh) 融合蛋白
Prada et al. Phase I clinical trial with a novel altered peptide ligand derived from human heat-shock protein 60 for treatment of rheumatoid arthritis: safety, pharmacokinetics and preliminary therapeutic effects
WO2016054218A1 (en) Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
JP5781514B2 (ja) Ｈｓｐ６５由来のペプチド６に特異的なヒト化抗体、その方法及び使用
US20250059290A1 (en) Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
US20070224191A1 (en) Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
JP2025000638A (ja) 抗ＩＦＮ－α／ω抗体の投与方法
EP4144763A1 (en) Bifunctional protein against pd-1 and tgf-beta
JP6430082B1 (ja) 低用量抗ｃｃｒ４抗体を用いたｈｔｌｖ−１関連脊髄症の予防または治療剤
KR20220012894A (ko) 전신 경화증의 치료 방법
CN119868536A (zh) 用于治疗癌症的组合疗法
JP2018024615A (ja) Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物
Santos et al. Portuguese recommendations for the use of biological therapies in children and adolescents with juvenile idiopathic arthritis--December 2011 update.
WO2026086834A1 (zh) 抗ox40抗体在治疗皮炎疾病中的用途
WO2025198912A1 (en) Methods of treating myasthenia gravis
Baldo Fusion Proteins
HK1181660A (en) Arthritis treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050604

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid